ID   MOLT-3/TMQ2500
AC   CVCL_S655
DR   Wikidata; Q54906360
RX   PubMed=2573416;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:9737; Trimetrexate.
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line).
CC   Derived from sampling site: Peripheral blood. Cell type=T-cell.
DI   NCIt; C9142; Adult T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0624 ! MOLT-3
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 23-06-22; Version: 13
//
RX   PubMed=2573416;
RA   Arkin H., Ohnuma T., Kamen B.A., Holland J.F., Vallabhajosula S.;
RT   "Multidrug resistance in a human leukemic cell line selected for
RT   resistance to trimetrexate.";
RL   Cancer Res. 49:6556-6561(1989).
//